Search bioRxiv⌕ Search

Biology subjects

Shahjaman, M.

Publications and source records attributed to Shahjaman, M..

3 recordsLinked to original sources

IPLS-LDA: An Improved Partial Least Square Discriminant Analysis for Heterogeneous Transcriptomics and Metabolomics Data Analysis

Supervised machine learning (SML) is an approach that learns from training data with known category membership to predict the unlabeled test data. There are many SML approaches in the literature and most of them use a linear score to learn its classifier. However, these approaches fail to elucidate biodiversity from heterogeneous biomedical data. Therefore, their prediction accuracies become low. Partial Least Square Linear Discriminant Analysis (PLS-LDA) is widely used in gene expression (GE) and metabolomics datasets for predicting unlabelled test data. Nevertheless, it also does not consider the non-linearity and heterogeneity pattern of the datasets. Hence, in this study, an improved PLS-LDA (IPLS-LDA) was developed by capturing the heterogeneity of datasets through an unsupervised hierarchical clustering approach. In our approach a non-linear score was calculated by combining all the linear scores obtained from the clustering method. The performance of IPLS-LDA was investigated in a comparison with six frequently used SML methods (SVM, LDA, KNN, Naive Bayes, RF, PLS-LDA) using one simulation data, one colon cancer gene expression data (GED) and one lung cancer metabolomics datasets. The resultant IPLS-LDA predictor achieved accuracy 0.841 using 10-fold cross validation in colon cancer data and accuracy 0.727 from two independent metabolomics data analysis. In both the cases IPLS-LDA outperformed other SML predictors. The proposed algorithm has been implemented in an R package, Uplsda was given in the https://github.com/snotjanu/UplsLda.

bioinformatics↗

Blood-based molecular biomarker signatures in Alzheimer’s disease: Insights from systems biomedicine analyses

Background and objectivesAlzheimers disease (AD) is the progressive neurodegenerative disease characterized by dementia, but no peripheral biomarkers available yet that can detect the AD. This study aimed to identify systems biomarker signatures in the AD through integrative analyses.\n\nMaterials and MethodsWe used two microarray transcriptomics datasets of blood from AD patients to identify differentially expressed genes (DEGs). Geneset and protein overrepresentation analysis, protein-protein interaction (PPI), DEGs-Transcription Factor interactions, DEGs-MicroRNAs interactions, protein-drug interactions, and protein subcellular localizations analyses were done on common DEGs.\n\nResultsTotal 25 DEGs were detected between the two datasets. Integration of DEGs with biomolecular networks revealed hub proteins (TUBB, ATF3, NOL6, UQCRC1, SND1, CASP2, BTF3, INPP5K, VCAM1, and CSTF1), TFs (FOXC1, ZNF3, GEMIN7, and SMG9), miRNAs (mir-20a-5p, mir-93-5p, mir-16-5p, let-7b-5p, mir-708-5p, mir-24-3p, mir-26b-5p, mir-17-5p, mir-4270, and mir-4441). The analyses revealed candidate blood based biomarkers in the AD. We evaluated the histone modifications of the identified biomolecules. The hub genes and transcription factors (TFs) revealed that they possess several histone modification sites associated with Alzheimers disease. The protein-drug interactions revealed 10 candidate drugs consisting of antineoplastic (Vinorelbine, Vincristine, Vinblastine, Epothilone D, Epothilone B, CYT997, and ZEN-012), dermatologicals (Podofilox), and immunosuppressive agents (Colchicine) that may target the candidate systems biomarkers. The subcellular localization analysis revealed the interactions of the DEGs range from nucleus to plasma membrane through cytosol.\n\nConclusionsThis study presents blood based systems molecular biomarker signatures at RNA and protein levels which might be useful as peripheral biomarkers in the AD. The candidate drugs, histone modification sites, and subcellular localizations will be useful in future drug design in the AD.

systems biology↗

Common molecular biomarker signatures in blood and brain of Alzheimers disease

BackgroundAlzheimers disease (AD) is a progressive neurodegenerative disease characterized by memory loss and confusion. Neuroimaging and cerebrospinal fluid-based early detection is limited in sensitivity and specificity as well as by cost. Therefore, detecting AD from blood cell analysis could improve early diagnosis and treatment of the disease. The present study aimed to identify blood cell transcripts that reflect brain expression levels of factors linked to AD progression.\n\nMethodsWe analyzed blood cell and brain microarray gene expression datasets from NCBI-GEO for AD association and expression in blood and brain. We also used eQTL and epigenetics data to identify AD-related genes that were regulated similarly in blood and brain.\n\nResultsWe identified 9 differentially expressed genes (DEG; AD versus controls) common to blood cells and brain (CNBD1, SUCLG2-AS1, CCDC65, PDE4D, MTMR1, C3, SLC6A15, LINC01806, and FRG1JP) and 18 genes (HSD17B1, GAS5, RPS5, VKORC1, GLE1, WDR1, RPL12, MORN1, RAD52, SDR39U1, NPHP4, MT1E, SORD, LINC00638, MCM3AP-AS1, GSDMD, RPS9, and GNL2) that were commonly dysregulated between AD blood and brain tissues using SNP and cis-eQTL data. This data revealed significant neurodegeneration-associated molecular pathways in the ribosomal and complement systems. Integration of these different analyses revealed dys-regulation of hub transcription factors (SREBF2, NR1H2, NR1H3, PRDM1, XBP1) and microRNAs (miR-518e, miR-518a-3p, miR-518b, miR-518c, miR-518d-3p and miR-518f) in AD. Several significant histone modification sites in DEGs were also identified.\n\nConclusionWe have identified new putative links between pathological processes in brain and transcripts in blood cells in AD subjects that may enable the use of blood to diagnose and monitor AD onset and progression.

neuroscience↗